PR News

"Various advancements in the technology have opened up numerous areas of opportunity for the growth of Cartilage Repair and Regeneration Market", says RNCOS.

Expands Amnion-Derived Allograft Products for Wound Care in Surgical, Orthopedic, Pediatric, Ophthalmic and Maxillofacial applications

Legal advisor and policy analyst to provide opening keynote on the Impact of the General Data Protection Regulation (GDPR) on collaborative science in Europe

Tom Kottler to be recognized today for his innovative use of technology to transform healthcare

Woodland Biosciences is a preclinical contract research organization specializing in in vivo oncology and metabolic diseases.

Biosceptre's appointment of a CMO marks a major milestone in progression to the clinic of its therapeutic anticancer vaccine BIL06v against the novel oncology target nfP2X7.

Discover how disaster drives innovation as the healthcare of catastrophes is discussed at this year's event.

Personalized Gene Therapy Treatments for Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

DelveInsight's, "Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2017", the report provides comprehensive insights about microbiome based therapeutic pipeline products.

Suvoda LLC, a SaaS provider of Interactive Response Technology (IRT) for clinical trial randomization and drug supply chain management, today announced that its CEO Jagath Wanninayake has been selected as a finalist for the Entrepreneur of the YearÒ2017..

Scientific and technological breakthroughs are changing the way doctors treat and manage diseases. However, many developing nations across Africa still lack basic resources and infrastructure to provide quality healthcare.

Prytime Medical Devices, Inc. (The REBOA Company™), a privately held medical technology company focused on minimally invasive solutions for trauma, has signed an exclusive distribution agreement with Combat Medical Systems as its U.S.

BOERNE, Texas - April 24, 2017 - PRLog -- Prytime Medical Devices, Inc. (The REBOA Company™), a privately held medical technology company focused on minimally invasive solutions for trauma, has signed an exclusive distribution agreement with Combat Medical Systems as its U.S. Military distributor. Combat Medical Systems will lead the sales and distribution of Prytime Medical's products to the U.S. Military and Federal Government.
Prytime Medical's flagship product, the ER-REBOA™ Catheter, provides clinicians with a tool to control bleeding and stabilize patients in hemorrhagic shock utilizing a minimally invasive technique called REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta). The catheter was designed specifically for the emergency and critical care environment.

"We are pleased to partner with Combat Medical Systems as our exclusive US Military distributor.  This partnership allows us the opportunity to better support the U.S. Department of Defense in particular," said David Spencer, President and CEO of Prytime Medical. "You dance with the one that brought you. This technology and technique arose from the Military and lessons learned from war. We are applying it to civilian trauma here back home. Now, Combat Medical Systems' depth of experience working with the Military positions us to better support the original reason we exist – to support combat wounded and those who treat them."

Combat Medical Systems was founded by a team of military medical personnel and industry specialists, and has a straightforward goal: simplify tactical medicine and decrease pre-hospital mortality. Their meaningful DoD relationships and first hand understanding of the tactical environment provide the company a strong position from which to support military medical needs.

About REBOA

REBOA (Resuscitative Endovascular Occlusion of the Aorta) is a minimally invasive technique to temporarily occlude large vessels by using a balloon catheter. Leading trauma centers across the US are adopting REBOA as a vital temporizing adjunct to control hemorrhage, which has been identified as the number one cause of potentially survivable death in the surgical, emergency, and critical care environment.

About Prytime Medical Devices (The REBOA Company™)

Prytime medical is an innovative medical device company that designs, develops and commercializes minimally invasive solutions for trauma. The company's flagship product is the ER-REBOA™ Catheter, a patented 7 Fr compatible balloon catheter for temporary occlusion of large vessels and pressure monitoring. In addition, the company is developing multiple next generation REBOA catheters and other minimally invasive solutions of interest. More information can be found at www.prytimemedical.com or by calling (210) 340-0116.

http://prytimemedical.com

Twitter: @prytimemedical

Toft Group Executive Search, a global life sciences and healthcare executive recruiting firm, today announced Michael Young has joined as Director based at the company's headquarters in San Diego, CA. In this role, Mr.

SAN DIEGO - April 21, 2017 - PRLog -- Toft Group Executive Search, a global life sciences and healthcare executive recruiting firm, today announced Michael Young has joined as Director based at the company's headquarters in San Diego, CA. In this role, Mr. Young will focus on placing Director through Executive Level positions for the company's pharmaceutical, biotech, medical device, technology, and diagnostic clients.

"Mr. Young brings an incredibly dynamic background to Toft Group that includes over 14 years as a Clinical Research Scientist, and a successful track record of recruiting at leading firms," commented Robin Toft, President & CEO of Toft Group. "He will be an outstanding addition to our world-class team as we continue to meet a growing demand for highly-skilled leadership in Life Sciences."

Mr. Young joins Toft Group from National Search Associates (NSA), where he served as Director of Business Development and Sales. Prior to NSA, Michael also served as an Executive Search Consultant with The Newport Group, and was Business Development and Recruiter with Kelly Services, a leading worldwide scientific staffing provider. During his years as a Pre-Clinical Research Scientist, Mr. Young developed/ designed several small molecule and biologics through in vivo and bench assay screens. He began his career as an R&D Scientist with a focus on Immunology and Metabolic disease.  Mr. Young spent 12 years with The Genomics Institute of the Novartis Research Foundation (GNF), where many of his projects are now into Clinical Testing within the Novartis pipeline.

About Toft Group Executive Search

Toft Group Executive Search is "Changing the Future of Medicine, One Relationship at a Time" and we take pride in the fact that our work helps our clients accelerate getting novel products to market. Named a Top 150 Fastest Growing Private Company (http://www.thetoftgroup.com/news-and-events/press/toft-gr...) and a Top 50 Executive Search Firm in Life Sciences (http://www.thetoftgroup.com/news-and-events/press/toft-gr...), we are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries.  Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego and Boston, we assist a wide range of local, national and international companies - from venture backed start-ups to Fortune 500 corporations.

Edupliance announces webinar titled, "Implications of the Trump Administration for the FDA" that aims to update attendees on the Trump administration policies, potential regulatory changes, and budget cuts that will have major implications for FDA...

http://chemiclabs.com Chemic Laboratories Inc. and Tamarack today announced establishment of a formal three year renewable Joint Cooperation Agreement.

Altor's IL-15 Superagonist Molecule, ALT-803, is currently part of an extensive development program, including ongoing Phase 3 Clinical Trials